ROR1-specific CAR T cells

ROR1-specific CAR T cells are autologous or allogeneic T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR) that targets the receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is an oncofetal protein with limited expression in normal adult tissues but is highly expressed in several hematologic malignancies (such as chronic lymphocytic leukemia) and solid tumors including triple-negative breast cancer and non-small cell lung cancer. The therapy involves isolating patient or donor T cells, modifying them ex vivo to express a synthetic receptor specific for ROR1—often using viral vectors or transposon systems—and then expanding and reinfusing these modified cells into the patient after lymphodepletion. The engineered CAR typically includes an scFv targeting domain for ROR1, costimulatory domains such as 4-1BB or CD28, and a CD3ζ signaling domain. Some constructs also include safety switches like truncated EGFR for potential elimination of the infused product in case of toxicity[2][3][7]. Clinical studies have shown promising antitumor activity in hematologic cancers like CLL but more limited efficacy in solid tumors due to challenges with tumor infiltration and persistence[7][9]. Safety concerns include cytokine release syndrome and organ toxicities related to on-target/off-tumor effects because low-level expression of ROR1 can occur on some normal tissues[5][6]. Multiple companies are developing clinical-grade manufacturing protocols using both viral-based and virus-free gene transfer technologies.

Brand names

LYL797LYL-797LYL 797

Other names

ROR1-targeted chimeric antigen receptor T cellsROR-1-targeted chimeric antigen receptor T cellsROR 1-targeted chimeric antigen receptor T cellsanti-ROR1 CAR-T cellsanti-ROR-1 CAR-T cellsanti-ROR 1 CAR-T cells